Starting biologic therapy at diagnosis, rather than escalating later, may significantly reduce complications and ...

New long-term data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through ...

"Eli Lilly’s Omvoh achieves 91% Crohn’s steroid-free remission at three years" was originally created and published by ...

Researchers identify a distinct blood viral profile in Crohn’s disease, suggesting circulating bacteriophages may serve as a novel disease marker.

Eli Lilly and Co. LLY on Thursday released promising long-term data regarding its treatment for Crohn’s disease. This news comes as the company reported that more than 90% of patients maintained ...

A new clinical trial suggests that changing when you eat could make a meaningful difference for people living with Crohn’s ...

A genetics‑guided drug, compound 6, targets CARD9 to subtly calm gut inflammation in Crohn’s disease, pointing to safer, longer‑lasting, precision treatments.

Time-restricted feeding can reduce clinical disease activity in Crohn disease in people with overweight or obesity, including those in remission.

Eli Lilly said new long-term data showed its Omvoh treatment resulted in durable efficacy for three years in adults with moderately to severely active Crohn's disease.

Intermittent fasting may help adults with Crohn’s disease and overweight or obesity lose weight and reduce systemic inflammation and disease activity.Data from a randomized controlled trial showed ...

Hispanic patients with inflammatory bowel disease (IBD) have varying disease patterns depending on their genetic ancestry, ...

NYU researchers have found a microbial signature of pediatric Crohn's disease that differs from the makeup of gut bacteria in ...